We are live on ! Find out more
ARMP icon

Armata Pharmaceuticals

25 hedge funds and large institutions have $473K invested in Armata Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

11% more capital invested

Capital invested by funds: $427K → $473K (+$46K)

4% more funds holding

Funds holding: 2425 (+1)

Holders
25
Holders Change
+1
Holders Change %
+4.17%
% of All Funds
0.54%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change

ARMP Hedge Fund Activity: Q1 2019 in Review

25 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q1 2019, worth a combined $473K — up 11% from $427K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ARMP positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $54.6K. The largest seller was Sabby Management, exiting entirely with an estimated $168K sold.

  • 25 institutional investors held Armata Pharmaceuticals (ARMP) as of Q1 2019, up from 24 in Q4 2018.
  • Funds reported $473K of Armata Pharmaceuticals stock for Q1 2019, up 11% quarter-over-quarter.
  • 4 funds opened new Armata Pharmaceuticals positions in Q1 2019 and 3 closed out, a net change of +1 holder.
  • The largest Armata Pharmaceuticals buyer in Q1 2019 was Renaissance Technologies, an estimated $54.6K added.
  • The largest Armata Pharmaceuticals seller in Q1 2019 was Sabby Management, an estimated $168K sold.

Based on aggregated 13F filings for Q1 2019.